カテゴリ： GlobalData, アメリカ, 企業調査

Advaxis Inc (ADXS)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Advaxis Inc (ADXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10001
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：89
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Advaxis Inc (Advaxis) is a biotechnology company that focuses on the discovery, development and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology that uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T cells directed against a cancer antigen, and lessen factors that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Under the Lm Technology platform, the company has four immunotherapy candidates in development, Axalimogene filolisbac (AXAL) in Human Papilloma Virus (HPV)-associated cancers; Neoantigen Therapy (ADXS-NEO); ADXS-PSA in prostate cancer; and ADXS-HER2 in HER2-expressing solid tumors. Advaxis is headquartered in Princeton, New Jersey, the US.

Advaxis Inc (ADXS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10
Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advaxis Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Advaxis and Bristol-Myers Squibb Enter into Agreement 13
Amgen Forms Partnership with Advaxis 14
Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15
Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16
Advaxis Enters into Research Agreement with Sorrento Therapeutics 17
Advaxis Enters into Agreement with Merck 18
Advaxis Enters into Agreement with MedImmune 19
Licensing Agreements 20
OS Therapies Enters into Licensing Agreement with Advaxis 20
Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21
Knight Therapeutics Enters into Licensing Agreement with Advaxis 22
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23
Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26
Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28
Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30
Equity Offering 31
Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31
Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33
Advaxis Prices Public Offering of Shares for USD20 Million 34
Advaxis Raises USD30.3 Million in Private Placement of Shares 36
Advaxis Raises USD25 Million in Private Placement of Shares 37
Advaxis Raises USD61.2 Million in Public Offering of Shares 39
Advaxis Raises USD23 Million in Private Placement of Common Stock 41
Advaxis Raises USD17 Million in Private Placement of Shares 43
Advaxis Raises USD14 Million in Public Offering Of Shares 45
Advaxis Completes Public Offering Of Shares For US$26.5 Million 46
Advaxis Announces Private Placement Of Common Stock For US$10 Million 47
Advaxis Inc – Key Competitors 48
Advaxis Inc – Key Employees 49
Advaxis Inc – Locations And Subsidiaries 50
Head Office 50
Recent Developments 51
Financial Announcements 51
Sep 10, 2018: Advaxis reports fiscal 2018 third quarter financial results 51
Jun 07, 2018: Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results 53
Mar 12, 2018: Advaxis Announces Q1 Fiscal 2018 Financial Results 55
Dec 20, 2017: Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update 57
Sep 11, 2017: Advaxis Reports Business Update and Third Quarter 2017 Results 59
Corporate Communications 61
Jun 06, 2018: Advaxis Appoints Molly Henderson as Chief Financial Officer 61
Jul 06, 2017: Advaxis Announces Change in Leadership 62
Apr 19, 2017: Advaxis Appoints Anthony Lombardo as Chief Business Officer 63
Product News 64
Jun 01, 2017: Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis’ Clinical Trials 64
03/26/2018: Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018 65
03/12/2018: Advaxis Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI (Durvalumab) 66
01/29/2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies 67
01/25/2017: New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported 68
Product Approvals 69
Jul 13, 2018: Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab 69
Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union 70
Mar 23, 2017: EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer 71
Clinical Trials 72
Apr 17, 2018: Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting 72
Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer 73
Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders 74
Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 75
May 18, 2017: Advaxis to Host Investor & Analyst Day on June 12 76
Mar 27, 2017: Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac 77
Mar 15, 2017: Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer 78
Feb 06, 2017: Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer 80
Jan 30, 2017: GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer 81
Other Significant Developments 82
Jul 10, 2018: Advaxis Provides Update on MAA Filing and ADXS-HOT Program 82
Jun 13, 2017: Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day 83
Jan 09, 2017: Advaxis Provides 2017 Business Outlook 86
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89

List of Tables
Advaxis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advaxis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10
Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advaxis and Bristol-Myers Squibb Enter into Agreement 13
Amgen Forms Partnership with Advaxis 14
Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15
Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16
Advaxis Enters into Research Agreement with Sorrento Therapeutics 17
Advaxis Enters into Agreement with Merck 18
Advaxis Enters into Agreement with MedImmune 19
OS Therapies Enters into Licensing Agreement with Advaxis 20
Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21
Knight Therapeutics Enters into Licensing Agreement with Advaxis 22
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23
Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26
Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28
Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30
Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31
Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33
Advaxis Prices Public Offering of Shares for USD20 Million 34
Advaxis Raises USD30.3 Million in Private Placement of Shares 36
Advaxis Raises USD25 Million in Private Placement of Shares 37
Advaxis Raises USD61.2 Million in Public Offering of Shares 39
Advaxis Raises USD23 Million in Private Placement of Common Stock 41
Advaxis Raises USD17 Million in Private Placement of Shares 43
Advaxis Raises USD14 Million in Public Offering Of Shares 45
Advaxis Completes Public Offering Of Shares For US$26.5 Million 46
Advaxis Announces Private Placement Of Common Stock For US$10 Million 47
Advaxis Inc, Key Competitors 48
Advaxis Inc, Key Employees 49

List of Figures
Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Advaxis Inc (ADXS)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • KBR Inc (KBR)-石油・ガス分野：企業M&A・提携分析
    Summary KBR, Inc. (KBR) is a global provider of engineering, construction, and professional services and technologies. It offers specialized engineering and design, technology licensing, program management, construction management, specialized consulting, operations, maintenance and other support se …
  • Banco Santander SA：企業の戦略・SWOT・財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Lonza Group Ltd (LONN)：企業の財務・戦略的SWOT分析
    Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Luna Innovations Inc (LUNA)：企業の製品パイプライン分析
    Summary Luna Innovations Inc (Luna) is an optical technology development company that research, develops and commercializes speed optics and fiber optic test products. The company provides products such as fiber optic sensing products, fiber optic test and measurement products, high speed optical pr …
  • NCC Group PLC (NCC)：企業の財務・戦略的SWOT分析
    NCC Group PLC (NCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Trinidad Drilling Ltd (TDG)：企業の財務・戦略的SWOT分析
    Summary Trinidad Drilling Ltd (Trinidad Drilling) is an oil and gas company that offers drilling services. The company’s services include land and barge drilling, coring and presetting, well servicing, rig design and management, rig fleet management, and technical support services. Its in-house manu …
  • Centrica Plc (CNA)-エネルギー分野：企業M&A・提携分析
    Summary Centrica plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF Energy Nuclear Generation. Centrica secures and supply gas and electricity to homes a …
  • Marathon Oil Corporation：企業の戦略・SWOT・財務情報
    Marathon Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Marathon Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Thetis Pharmaceuticals LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary Thetis Pharmaceuticals LLC (Thetis Pharma) is a drug manufacturing company that offers novel immuno-resolving therapies. The company develops and manufactures drugs for type two diabetes and chronic conditions. Its pipeline products include TP252, TP6211, TP113, and TP 101. Thetis Pharma’s T …
  • Blueprint Medicines Corp (BPMC)：企業の財務・戦略的SWOT分析
    Summary Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, discovers and develops precision therapies for the treatment of cancers and rare diseases. The company offers AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST); and GAVRETO (pralse …
  • Seplat Petroleum Development Company Plc (SEPLAT)：企業の財務・戦略的SWOT分析
    Summary Seplat Petroleum Development Company Plc (Seplat) is an independent upstream exploration and production company that offers development and operation of oil and natural gas reserves and production assets. The company produces oil from fileds such as Amukpe, Oben, Okporhuru, Ovhor, Orogho, Sa …
  • CardioDx Inc：企業の戦略的SWOT分析
    CardioDx Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • United Surgical Partners International Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary United Surgical Partners International Inc (United Surgical Partners) is a healthcare service provider that offers ambulatory surgical services. The center provides services in the therapeutical areas of orthopedic, pain management, gynaecology, general surgery, ear, nose, and throat, endosc …
  • Miragen Therapeutics Inc (MGEN)：医療機器：M&Aディール及び事業提携情報
    Summary Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), …
  • Seafarms Group Ltd (SFG)：企業の財務・戦略的SWOT分析
    Seafarms Group Ltd (SFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Damodar Valley Corporation：発電所・企業SWOT分析
    Damodar Valley Corporation – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Naim Holdings Berhad：企業の戦略・SWOT・財務情報
    Naim Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary Naim Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • VAALCO Energy, Inc. (EGY)-石油・ガス分野：企業M&A・提携分析
    Summary VAALCO Energy, Inc. (VAALCO) is an upstream energy company. It acquires, explores, develops and produces crude oil and natural gas. The company conducts exploration activities as operator in Gabon and as a non-operator in Equatorial Guinea, West Africa. VAALCO also owns minor in certain non- …
  • Scottish and Southern Energy plc：企業の戦略・SWOT・財務情報
    Scottish and Southern Energy plc - Strategy, SWOT and Corporate Finance Report Summary Scottish and Southern Energy plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Suntory Holdings Ltd：戦略・SWOT・企業財務分析
    Suntory Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Suntory Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆